MINNEAPOLIS, MN, ProEncia Biotechnology, a biopharma startup, has announced the company has closed significant pre-seed funding to advance its next-generation periodontal disease treatment.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.